Homburger advises VectivBio on its follow-on public offering and concurrent private placement

On June 14, VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the pricing of a follow-on public offering of ordinary shares in the United States, raising gross proceeds of USD 30 m. In addition, VectivBio has agreed to a concurrent private placement of ordinary shares for gross proceeds of approximately USD 20 m.

The Homburger team includes partner Andreas Müller and lead associate Margrit Marti (both Capital Markets; Corporate / M&A), associates Kevin Hubacher, Angela Oppliger and Oliver Kneubühl (all Corporate / M&A), and partner Stefan Oesterhelt and associate Kevin Müller (both Tax).